Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
, 6, 21-6
eCollection

Dorzolamide Chlorhydrate Versus Acetazolamide in the Management of Chronic Macular Edema in Patients With Retinitis Pigmentosa: Description of Three Case Reports

Affiliations
Case Reports

Dorzolamide Chlorhydrate Versus Acetazolamide in the Management of Chronic Macular Edema in Patients With Retinitis Pigmentosa: Description of Three Case Reports

Elena Pacella et al. Ophthalmol Eye Dis.

Abstract

Aims: To assess the efficacy of topical dorzolamide for treating cystoid macular edema in patients with retinitis pigmentosa and minimize the secondary effects of maintenance therapy in patients with retinitis pigmentosa (RP) who present with chronic microcystic macular edema.

Methods: To replace acetazolamide systemic treatment, with a topical treatment using 2% dorzolamide in three patients. The methods performed were OCT scan with a Spectralis HRA-OCT, for the measurement of macular thickness and morphology; best corrected visual acuity was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS), was assessed slit-lamp biomicroscopy, ocular tonometry, fundus biomiocrosopy, and color fundus photography. This therapeutic protocol has been applied and described in three patients.

Results: In all three tested patients, following the administration of dorzolamide in eye drop, we observed a remarkable decrease in macular edema, almost comparable to that obtained with acetazolamide per os.

Conclusion: The study confirms the anti-edematogenic effect of topical dorzolamide in RP with recurring macular cysts, as this can have a favorable response with topical dorzolamide. In all the three examined patients, the instillation of topical dorzolamide caused a remarkable reduction in their macular edema, as highlighted on OCT.

Keywords: acetazolamide; cystoid macular edema; dorzolamide; retinitis pigmentosa.

Figures

Figure 1
Figure 1
Images of the right eye at baseline (T0) optical coherence tomography (OCT), central macular thickness (CMT) 551, 3 weeks after starting treatment CMT 401, 6 months after starting treatment (T2) CMT 376.
Figure 2
Figure 2
Images of the left eye at baseline (T0) optical coherence tomography (OCT), central macular thickness (CMT) 463, 3 weeks after starting treatment CMT 330, 6 months after .starting treatment (T2) CMT 322.
Figure 3
Figure 3
Images of the right eye at at baseline (T0) optical coherence tomography (OCT), CMT 455, 3 weeks after starting treatment CMT 357, 6 months after starting treatment (T2) CMT 340.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Kellner U, Renner AB, Tillack H. Hereditary retinochoroidal dystrophies. Part 2: differential diagnosis. Ophthalmologe. 2004;101(4):397–412. quiz 413. German. - PubMed
    1. Souied E, Soubrane G, Coscas G. Hereditary retinal diseases. Rev Prat. 1996;46(14):1730–6. French. - PubMed
    1. Schmidt JG, Zinser J. Long-term follow-up of deterioration of the visual field in visual acuity in retinitis pigmentosa. Fortschr Ophthalmol. 1989;86(6):614–8. German. - PubMed
    1. Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm. 2002;10(4):239–46. - PubMed
    1. Fishman GA, Gilbert LD, Fiscella RG, Kimura AE, Jampol LM. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol. 1989;107(10):1445–52. - PubMed

Publication types

LinkOut - more resources

Feedback